
Aimee Tharaldson, PharmD, senior clinical consultant, Emerging Therapeutics, Express Scripts, Inc, discussed the 351K pathway and compared it with the biologic licensing application (BLA) submission route for biosimilar drugs at the Academy of Managed Care Pharmacy's Educational Conference.





























